Global

Pharma companies face unique challenges with market access in this region.

Three of the new sites will focus primarily on producing ingredients for domestic usage.

Pathways to success for this key component of Europe’s new HTA regulation, where thinking beyond the purely technical will be critical.

The importance of a strategic approach and proper due diligence in unlocking the full potential of these arrangements.

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

Pharma looks to take advantage of expanded access programs across Asia-Pacific region.

EVERSANA's Ryan discusses the company’s recent expansion into new markets in Europe.

The president of compliance services discusses the company’s recent expansion into new markets.

In an interview with Pharm Exec Associate Editor Don Tracy, Joseph Mikhael, chief medical officer, IMF, offers a glimpse at multiple initiatives that the IMF is working towards to improve myeloma treatment globally.

The region is moving to the forefront in integrating therapeutic innovation.

Is it possible to win in Asia’s private market?

The three key themes likely to shape pharma fortunes in 2024.

A growing number of domestic drug developers are setting their sights on overseas markets.

An overview of what biopharma C-Suites and their boards should consider when engaging with government and business leaders from China, the world’s second largest economy.

Raja discusses how the pharma industry can improve its ecological impact.

Effective engagement—from research to reimbursement—is key.

The treatment is approved for conditional marketing authorization.

Attempts to capitalize on the region’s vibrant R&D scene are heating up.

Some new EU plans "fly in the face" of innovation, critics contend.

Advancing the concept of "health competencies" remains elusive.

More opinions enter the mix as EU launches legislation review.

The UK BioIndustry Association and Clarivate detail current economic trends in the UK Biotech Financing Report.

The time is ripe to double down on local “market-fit” capabilities.

US pharma industry handcuffed by restrictions, group argues.

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.

An ecosystem perspective is the first step.

Member states air concerns over excess supplies of COVID vaccines.

Making sense of surprise rejection of draft proposals.